Good
Mostly Aligned
Patient Risk:
Low
Summary
Most high-level statements match the label (indication categories, IV infusion, lack of contraindications, branded product). However, several important details are oversimplified or incomplete (NSCLC indication is mutation-specific and is combination-specific; side-effect examples are not fully supported; monitoring/infusion-reaction handling is not described accurately), reducing overall alignment.
Category Scores
Accurate Statements
Cyramza (ramucirumab) is an anti-cancer medicine used in certain solid tumors.
Sections 1 (indications) and 12/14 context provided in excerpts relate to cancer treatment across solid tumors (gastric, NSCLC, colorectal, HCC).
Cyramza is administered by intravenous (IV) infusion in a clinical setting.
Section 2.2 and 2.7 describe administration by intravenous infusion; Section 2.1 and preparation instructions support infusion administration.
The dosing schedule for Cyramza depends on the indication and whether it is used alone or with other therapies.
Section 2.2–2.5 shows different regimens (e.g., gastric 8 mg/kg q2weeks +/- weekly paclitaxel; NSCLC 10 mg/kg q2weeks with erlotinib vs 10 mg/kg on Day 1 of a 21-day cycle with docetaxel; colorectal 8 mg/kg q2weeks with FOLFIRI; HCC 8 mg/kg q2weeks).
Serious risks with Cyramza can include bleeding.
Section 5.1 Hemorrhage lists hemorrhage and GI hemorrhage risk and severity; Section 6 references hemorrhage as a serious adverse reaction described elsewhere.
Serious risks with Cyramza can include blood pressure problems.
Section 5.5 Hypertension discusses increased incidence of severe hypertension; Section 6 references hypertension as a serious adverse reaction described elsewhere.
Bleeding and blood pressure problems are monitored during treatment with Cyramza.
Section 5.5 includes monitoring blood pressure every two weeks. Section 5.1 describes management including discontinuation for severe bleeding; the provided excerpt does not explicitly state a bleeding monitoring schedule, but management/clinical monitoring is implied by the safety section. (Partial label support.)
Cyramza is a branded oncology product.
The label excerpt uses the proprietary name CYRAMZA and is an FDA-approved prescription product.
Cyramza is used for specific indications in gastric or gastroesophageal junction cancer.
Section 1.1 Gastric Cancer indication.
Cyramza is used for specific indications in non-small cell lung cancer (NSCLC).
Section 1.2 NSCLC indications.
Unsupported Statements
Common patient-relevant side effects with Cyramza can include fatigue.
The provided label excerpts do not list fatigue as a common patient-relevant adverse reaction.
Common patient-relevant side effects with Cyramza can include nausea.
The provided label excerpts do not list nausea as a common patient-relevant adverse reaction.
Common patient-relevant side effects with Cyramza can include decreased appetite.
The provided label excerpts do not list decreased appetite as a common patient-relevant adverse reaction.
Common patient-relevant side effects with Cyramza can include infusion-related reactions.
The label excerpt confirms infusion-related reactions occur and provides precautions/premedication, but does not support the claim that they are 'common patient-relevant side effects' in the sense of frequency/commonality (frequency data not provided in excerpts).
Patent and exclusivity status for Cyramza depends on the specific country and the formulation/indication.
The provided FDA label excerpts do not address patent/exclusivity status.
Contradictions
Low
AI Statement
Bleeding and blood pressure problems are monitored during treatment with Cyramza.
Label Reference
Section 5.5 explicitly states blood pressure monitoring; Section 5.1 excerpt provided does not explicitly specify a monitoring method/schedule for bleeding.
Important Omissions
NSCLC indication is mutation- and combination-specific (EGFR exon 19 deletions or exon 21 L858R mutations with erlotinib for first-line metastatic NSCLC; and with docetaxel after platinum-based chemotherapy progression with additional requirement to have progressed on FDA-approved therapy for EGFR/ALK aberrations).
Importance:
Moderate
Premedication and infusion-related reaction management details (e.g., prior IV histamine-1 antagonist before each infusion; additional dexamethasone and acetaminophen after Grade 1–2 IRR; infusion rate reduction and discontinuation guidance for higher-grade IRR).
Importance:
Moderate
Preparation/administration constraints: dilute with only 0.9% Sodium Chloride, do not shake, do not use IV push/bolus, use separate infusion line, do not co-infuse with other electrolytes/medications, and recommended filter.
Importance:
Moderate
Contraindications statement is 'None' (omission not present as AI did not discuss contraindications), but the AI also did not explicitly state 'none.' This is only relevant if evaluating contraindications; otherwise not material.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No direct dosing instructions were given that would clearly conflict with the label. However, oversimplified and partially unsupported adverse-effect frequency claims (fatigue/nausea/decreased appetite) and incomplete NSCLC indication specificity could lead to inaccurate patient counseling or study of indications. The claims about serious risks (bleeding, hypertension) generally align with the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Incomplete/oversimplified indication details for NSCLC and unsupported 'common' frequency assertions for several side effects not present in the provided excerpts.
Suggested Improvement
Specify NSCLC molecular/line-of-therapy requirements from Section 1.2 and avoid labeling fatigue/nausea/decreased appetite as common unless supported by the provided label frequency text; add key IRR premedication and infusion-management instructions from Section 2.1 and 5.6 if describing infusion-related reactions.